Genprex
GNPX
18 hedge funds and large institutions have $5.8M invested in Genprex in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 2 closing their positions.
223% more call options, than puts
Call options by funds: $384K | Put options by funds: $119K
0% less ownership
Funds ownership: 0% → 0% (-0%)
5% less funds holding
Funds holding: 19 → 18 (-1)
8% less capital invested
Capital invested by funds: $6.28M → $5.8M (-$487K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
80% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$56.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
-$113K |
| 2 |
Millennium Management
New York
|
-$113K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$113K |
| 4 |
Renaissance Technologies
New York
|
-$56.5K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$56.5K |
GNPX Hedge Fund Activity: Q4 2022 in Review
18 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q4 2022, worth a combined $5.8M — down 7.7% from $6.28M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of GNPX and 1 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $56.5K. The largest seller was Group One Trading, cutting an estimated $113K.
- 18 institutional investors held Genprex (GNPX) as of Q4 2022, down from 19 in Q3 2022.
- Funds reported $5.8M of Genprex stock for Q4 2022, down 7.7% quarter-over-quarter.
- 1 fund opened new Genprex positions in Q4 2022 and 2 closed out, a net change of -1 holder.
- The largest Genprex buyer in Q4 2022 was Citadel Advisors, an estimated $56.5K added.
- The largest Genprex seller in Q4 2022 was Group One Trading, an estimated $113K sold.
Based on aggregated 13F filings for Q4 2022.